TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Noxopharm Ltd. ( (AU:NOX) ) has provided an update.
Noxopharm Limited has successfully completed the third dose cohort in its HERACLES clinical trial for the novel drug candidate SOF-SKN™, aimed at treating autoimmune diseases. The trial, which is a double-blind study conducted in Australia, will now proceed to the highest dose cohort, with the safety steering committee confirming the safety and tolerability of the third dose. This trial is significant for Noxopharm’s positioning in the autoimmune treatment market, particularly with the global cutaneous lupus erythematosus market expected to grow significantly.
More about Noxopharm Ltd.
Noxopharm Limited is a clinical-stage biotech company focused on developing novel drug candidates for autoimmune diseases. The company leverages its Sofra technology platform, which targets inflammatory and autoimmune diseases, with potential applications in rheumatoid arthritis, lupus, diabetes, and other immune-related conditions.
Average Trading Volume: 290,268
Technical Sentiment Signal: Buy
Current Market Cap: A$33.61M
See more data about NOX stock on TipRanks’ Stock Analysis page.